{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:33:26Z","timestamp":1783020806682,"version":"3.54.6"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Belumosudil is an oral, selective inhibitor of Rho-associated coiled-coil\u2013containing protein kinase 2, approved for the treatment of chronic graft-versus-host disease (cGVHD). Clinical trials have shown that higher doses of belumosudil are associated with a greater incidence of adverse events. The pharmacokinetics of belumosudil are markedly affected by food intake and concurrent medications, and substantial interindividual variability in plasma concentrations has also been reported. Therefore, monitoring belumosudil blood concentrations may facilitate more effective drug therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Belumosudil and luliconazole (internal standard, IS) were extracted from 50 \u00b5L of human plasma using methanol. Chromatographic analysis was performed on a reversed-phase column (250 mm \u00d7 4.6 mm, 5 \u00b5m) under isocratic conditions, with a mobile phase of 0.5% KH\n                      <jats:sub>2<\/jats:sub>\n                      PO\n                      <jats:sub>4<\/jats:sub>\n                      (pH 4.5) and acetonitrile (40:60, v\/v) at a flow rate of 1 mL\/min. Ultraviolet detection was performed at 337 nm. The calibration curve for belumosudil demonstrated linearity over the concentration range of 250 to 15,000 ng\/mL, with a correlation coefficient (r\n                      <jats:sup>2<\/jats:sup>\n                      ) of 0.9998. The accuracy and precision of all validation experiments met the criteria established by the US Food and Drug Administration.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In this study, 44 plasma samples from 5 patients with cGVHD were analyzed to determine belumosudil concentrations. The chromatographic peaks of both the IS and belumosudil showed no interference from the biological matrix or from concurrent medications and their metabolites, confirming adequate selectivity and specificity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This study presents the first development and validation of a simple, novel, and broad-range high-performance liquid chromatography\u2013ultraviolet approach for quantifying plasma belumosudil, supporting its suitability for therapeutic drug monitoring in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001500","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T18:15:27Z","timestamp":1783016127000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Wide-Range Quantification of Belumosudil in Patients with Chronic Graft-Versus-Host Disease by High-Performance Liquid Chromatography"],"prefix":"10.1097","author":[{"given":"Yoshito","family":"Gando","sequence":"first","affiliation":[{"name":"Department of Medicinal Therapy Research, Education and Research Unit for Comprehensive Clinical Pharmacy, Meiji Pharmaceutical University, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikuru","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Medicinal Therapy Research, Education and Research Unit for Comprehensive Clinical Pharmacy, Meiji Pharmaceutical University, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Shimoda","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Satoh","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saori","family":"Aizawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0587-0091","authenticated-orcid":false,"given":"Takeo","family":"Yasu","sequence":"additional","affiliation":[{"name":"Department of Medicinal Therapy Research, Education and Research Unit for Comprehensive Clinical Pharmacy, Meiji Pharmaceutical University, Tokyo, Japan;"},{"name":"Department of Pharmacy, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Tsukada","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"R1-20260702","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1200\/JCO.20.02754","article-title":"ROCK2 inhibition with belumosudil (KD025) for the treatment of chronic graft-versus-host disease","volume":"39","author":"Jagasia","year":"2021","journal-title":"J Clin Oncol"},{"key":"R2-20260702","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2016-06-686618","article-title":"Chronic graft-versus-host disease: biological insights from preclinical and clinical studies","volume":"129","author":"MacDonald","year":"2017","journal-title":"Blood"},{"key":"R3-20260702","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1056\/NEJMra1703472","article-title":"Pathophysiology of chronic graft-versus-host disease and therapeutic targets","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"key":"R4-20260702","first-page":"504.e1","article-title":"Epidemiology and treatment of chronic graft-versus-host disease post-allogeneic hematopoietic cell transplantation: a US claims analysis","volume":"27","author":"Bachier","year":"2021","journal-title":"Transpl Cell Ther"},{"issue":"suppl l","key":"R5-20260702","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1016\/j.bbmt.2009.11.002","article-title":"Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease","volume":"16","author":"Chien","year":"2010","journal-title":"Biol Blood Marrow Transpl"},{"key":"R6-20260702","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1186\/s12890-025-03925-1","article-title":"Risk factors for bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation: a systematic review and meta-analysis","volume":"25","author":"Pu","year":"2025","journal-title":"BMC Pulm Med"},{"key":"R7-20260702","doi-asserted-by":"crossref","first-page":"6263","DOI":"10.1182\/bloodadvances.2022008095","article-title":"Clinical response to belumosudil in bronchiolitis obliterans syndrome: a combined analysis from 2 prospective trials","volume":"6","author":"DeFilipp","year":"2022","journal-title":"Blood Adv"},{"key":"R8-20260702","article-title":"Long-term follow-up of belumosudil as second or subsequent line of therapy for steroid-dependent\/resistant cGVHD: clinical outcomes from a Japanese study","author":"Kato","year":"2025","journal-title":"Bone Marrow Transpl"},{"key":"R9-20260702","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/cpdd.1083","article-title":"Phase 1 studies to evaluate the food effect and relative bioavailability of tablet and capsule formulations of belumosudil in healthy adult subjects","volume":"11","author":"Schueller","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"key":"R10-20260702","doi-asserted-by":"crossref","first-page":"e70265","DOI":"10.1111\/cts.70265","article-title":"Pharmacokinetics of belumosudil and its metabolites in individuals with hepatic impairment","volume":"18","author":"Schueller","year":"2025","journal-title":"Clin Transl Sci"},{"key":"R11-20260702","first-page":"224","article-title":"Evaluation of drug interactions in hospitalized patients with malignancy","volume":"16","author":"Hatefi","year":"2022","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"key":"R12-20260702","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/cpdd.1082","article-title":"A phase 1 pharmacokinetic drug interaction study of belumosudil coadministered with CYP3A4 inhibitors and inducers and proton pump inhibitors","volume":"11","author":"Schueller","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"key":"R13-20260702","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/cpdd.1142","article-title":"A phase 1 thorough QT\/QTc study of therapeutic and supratherapeutic doses of belumosudil in healthy subjects","volume":"11","author":"Schueller","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"key":"R14-20260702","article-title":"FDACDER, CVM; guidance for industry: bioanalytical method","year":"2018"},{"key":"R15-20260702","first-page":"838","article-title":"Efficacy and safety of once-daily luliconazole 1% cream in patients \u226512 years of age with interdigital tinea pedis: a phase 3, randomized, double-blind, vehicle-controlled study","volume":"13","author":"Jarratt","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"R16-20260702","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1128\/AAC.02370-12","article-title":"Safety and tolerability of luliconazole solution 10-percent in patients with moderate to severe distal subungual onychomycosis","volume":"57","author":"Jones","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"R17-20260702","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3999\/jscpt.54.5_197","article-title":"Safety, tolerability, and pharmacokinetics of belumosudil, a selective Rho-associated coiled-coil-containing protein kinase 2 inhibitor. In: Healthy Japanese volunteers: a Phase\u2160, Randomized, rontrolled Trial","volume":"54","author":"Ogama","year":"2023","journal-title":"Rinsho yakuri\/Japanese J Clin Pharmacol Ther"},{"key":"R18-20260702","doi-asserted-by":"crossref","first-page":"e0293873","DOI":"10.1371\/journal.pone.0293873","article-title":"The effect of oral chronic graft-versus-host disease on bodyweight: a cohort study","volume":"19","author":"Aboalela","year":"2024","journal-title":"PLOS One"},{"key":"R19-20260702","first-page":"zxaf270","article-title":"Serum belumosudil concentrations in a patient receiving a combination of 3 gastric acid-suppressing agents: a case report","author":"Araki","year":"2025","journal-title":"Am J Health Syst Pharm"},{"key":"R20-20260702","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1111\/bcp.16164","article-title":"Economic evaluations of therapeutic drug monitoring interventions in acute hospital-based settings: a systematic review","volume":"90","author":"Carland","year":"2024","journal-title":"Br J Clin Pharmacol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001500","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T18:15:30Z","timestamp":1783016130000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":20,"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001500","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"2025-12-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}